Birchview Capital LP lifted its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 64.7% in the 4th quarter, Holdings Channel reports. The fund owned 127,303 shares of the company’s stock after acquiring an additional 50,000 shares during the period. Oxford Immunotec Global comprises 1.0% of Birchview Capital LP’s investment portfolio, making the stock its 7th largest holding. Birchview Capital LP’s holdings in Oxford Immunotec Global were worth $1,778,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in OXFD. RTW Investments LP lifted its holdings in Oxford Immunotec Global by 21.9% during the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after buying an additional 185,453 shares in the last quarter. Wasatch Advisors Inc. lifted its holdings in Oxford Immunotec Global by 35.5% during the 3rd quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock valued at $9,646,000 after buying an additional 150,343 shares in the last quarter. Cortina Asset Management LLC lifted its holdings in Oxford Immunotec Global by 12.8% during the 3rd quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock valued at $9,463,000 after buying an additional 63,765 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Oxford Immunotec Global by 20.5% during the 2nd quarter. Teachers Advisors LLC now owns 55,674 shares of the company’s stock valued at $936,000 after buying an additional 9,474 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Oxford Immunotec Global by 31.3% during the 3rd quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock valued at $651,000 after buying an additional 9,235 shares in the last quarter. Hedge funds and other institutional investors own 89.30% of the company’s stock.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $11.73 on Monday. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38. The company has a market cap of $300.93, a PE ratio of -5.81 and a beta of -0.30. Oxford Immunotec Global PLC has a 12-month low of $10.81 and a 12-month high of $19.51.

OXFD has been the subject of a number of research analyst reports. BTIG Research set a $21.00 price objective on shares of Oxford Immunotec Global and gave the company a “buy” rating in a report on Tuesday, October 31st. Robert W. Baird reiterated a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. BidaskClub lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Finally, Cowen reiterated a “buy” rating and set a $15.00 price objective on shares of Oxford Immunotec Global in a report on Monday, January 22nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.75.

WARNING: “Oxford Immunotec Global PLC (OXFD) is Birchview Capital LP’s 7th Largest Position” was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-is-birchview-capital-lps-7th-largest-position/1845298.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.